Abstract: Actinomycin-based near IR emitting compounds and methods of their use as nucleic acid stains are provided.

Abstract: In some embodiments, an analyte detection system is provided that includes a nanochannel, an electrode arrangement, and a plurality of nanoFET devices disposed in the nanochannel. A plurality of nucleic acid base detection components can be used that include a plurality of nanopores, a plurality of nanochannels, a plurality of hybridization probes, combinations thereof, and the like. According to other embodiments of the present teachings, different coded molecules are hybridized to a target DNA molecule and used to detect the presence of various sequences along the target molecule. A kit including mixtures of coded molecules is also provided. In some embodiments, devices including nanochannels, nanopores, and the like, are used for manipulating movement of DNA molecules, for example, in preparation for a DNA sequencing detection. Nanopore structures and methods of making the same are also provided as are methods of nucleic acid sequencing using the nanopore structures.

Abstract: Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.

Abstract: Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients.

Abstract: The invention provides isolated nucleic acids molecules and proteins, designated NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, and NARC 25, nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.

Abstract: The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis.

Abstract: The present invention is related to a method for determining the nucleotide sequence of a nucleic acid molecule comprising the following steps: a) providing a plurality of molecules of the nucleic acid molecule having at least one modification; b) cleaving at random the plurality of modified nucleic acid molecules thus providing modified nucleic acid molecule fragments and non-modified nucleic acid molecule fragments; c) separating the modified nucleic acid molecule fragments from the non-modified nucleic acid molecule fragments; d) separating or resolving the modified nucleic acid molecule fragments according to their length, mass and/or charge, whereby such separating or resolving generates a pattern of modified nucleic acid fragments; and e) optionally visualizing the pattern of modified nucleic acid fragments.

Abstract: Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises inhibiting ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound, and then determining whether the compound inhibits the binding of that tRNA.

Abstract: Disclosed is a method for performing nucleic acid hybridization assays which involve the application of acoustic surface waves. The hybridization assays may be used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or associated with predisposition to various diseases. In a particular aspect, the present method relates to the use of rapid nucleic acid hybridization methods, such as comparative genomic hybridization (CGH), for comparing nucleic acid segments of one genome to corresponding nucleic acid segments in another genome(s).

Abstract: Embodiments of the invention relate generally to ferromagnetic microdisks, methods of detecting target bioanalyte using ferromagnetic microdisks, and kits (such as for using in the laboratory setting) containing the reagents necessary to make, and/or use ferromagnetic microdisks for bioanalyte detection, depending on the user's planned application. The methods and products allow the fabrication of ferromagnetic microdisks, and their use in the detection of biological molecules with high sensitivity, little or no signal decay, improved safety, convenience, and lowered cost for use and disposal.

Abstract: Methods for quantitatively determining a binding kinetic parameter of a molecular binding interaction are provided. Aspects of embodiments of the methods include: producing a magnetic sensor device including a magnetic sensor in contact with an assay mixture including a magnetically labeled molecule to produce a detectable molecular binding interaction; obtaining a real-time signal from the magnetic sensor; and quantitatively determining a binding kinetics parameter of the molecular binding interaction from the real-time signal. Also provided are systems and kits configured for use in the methods.

Abstract: The present invention relates to methods of identifying gene targets, including methods of using ribonucleoprotein (RNP) immunoprecipitation-microarrays to identify cancer gene targets, such as subsets of RNP-associated mRNAs in breast cancer cell lines. Also presented, are ribonucleotide binding protein-associated biomarkers, panels or sets of ribonucleotide binding protein-associated biomarkers, methods and compositions comprising ribonucleotide-binding protein, associated nucleotides, nucleotide arrays, and kits to facilitate the diagnosis of and monitoring the disease status or progression of treatment of breast cancers, including drug-resistant breast cancers.

Abstract: The present invention relates to diagnostic markers for hepatocellar carcinoma and a method for predicting and diagnosing susceptibility to hepatocellular carcinoma, and more particularly, to polymorphic markers for the diagnosis of hepatocellular carcinoma based on polymorphisms present in exons of the TGF?RIII gene represented by SEQ ID No. 1, a diagnostic composition for hepatocellular carcinoma using the same, a diagnostic kit, a microarray, and a method for diagnosing hepatocellular carcinoma. The polymorphic markers for the diagnosis of hepatocellular carcinoma according to the present invention are genetic markers useful to diagnose genetic susceptibility specific to hepatocellular carcinoma. With these markers, susceptibility to hepatocellular carcinoma can be comprehensively determined.

Abstract: Described are devices and methods for detecting binding on an electrode surface. In addition, devices and methods for electrochemically synthesizing polymers and devices and methods for synthesizing and detecting binding to the polymer on a common integrated device surface are described.

Abstract: The present invention relates to carboxamide-substituted dyes, the production and use of such dyes as labeling groups in analytics.

Abstract: Disclosed are nucleic acid-based molecular switches that respond to changes in pH. The switches may be used in DNA nanodevices. The switches may also act as sensors for measuring the pH of a sample, including cells, regions thereof, and whole organisms. The switch includes an A-motif that forms at acidic pH. Also disclosed are compositions and methods for measuring the pH of cells or regions thereof, such as vesicles, the nucleus, mitochondrial matrix, or the Golgi lumen.

Abstract: The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.

Abstract: Unsymmetrical cyanine dyes that incorporate an aza-benzazolium ring moiety are described, including cyanine dyes substituted by a cationic side chain, monomeric and dimeric cyanine dyes, chemically reactive cyanine dyes, and conjugates of cyanine dyes. The subject dyes are virtually non-fluorescent when diluted in aqueous solution, but exhibit bright fluorescence when associated with nucleic acid polymers such as DNA or RNA, or when associated with detergent-complexed proteins. A variety of applications are described for detection and quantitation of nucleic acids and detergent-complexed proteins in a variety of samples, including solutions, electrophoretic gels, cells, and microorganisms.

Abstract: The present invention relates to sensitive, rapid and convenient assays for detection and or quantification of one or more analyte(s) in solution using multivalent proximity probes. The proximity probes each comprise several binding moieties, such as antibodies, and associated nucleic acid(s). When the binding moieties have bound to their analyte(s), the nucleic acids on opposite proximity probes interact with each other and a signal is generated based on this interaction. The multivalent proximity probes are especially valuable for highly sensitive and specific protein detection.

Abstract: The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of modulated plant size, vegetative growth, organ number, plant architecture, sterility or seedling lethality in plants. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having such modulated growth or phenotype characteristics that are altered with respect to wild type plants grown under similar conditions.

Abstract: The present invention relates to a diagnostic technique related to a biomarker for a microdomain disease and a method for detecting a microdomain disease of which manipulation is easy and which is inexpensive.

Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided.

Abstract: The present disclosure provides methods of making isotopically-labeled glycans or a mixture of glycans (e.g., a glycan preparation) via reductive amination. Such methods are useful, for example, in the determination of the relative amounts of a glycan species present in two or more glycoprotein preparations using mass spectroscopy. In one aspect, the present disclosure provides a method of making an isotopically-labeled glycan by a glycan with an amine and an isotopically-labeled reducing agent to provide an isotopically-labeled aminated glycan. In certain embodiments, the amine is an isotopically-labeled amine.

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.

Abstract: The present disclosure is related to amplified fluorescence polymers (AFPs) with pendant functional groups, their derivatives and their synthesis. The amplified fluorescence polymers can be used in various biological and chemical sensors.

Abstract: A method for labeling a product includes a step of adding on or in the product a plurality of single-stranded polynucleotides, which plurality of polynucleotides includes at least one target polynucleotide constituted of a single-stranded polynucleotide of predetermined length and sequence, and decoy polynucleotides which have identical or different predetermined lengths and identical or different predetermined sequence, which decoy polynucleotides have a length or lengths identical to or different from and sequences different from the sequence of the at least one target polynucleotide, wherein each of the target and decoy polynucleotides does not hybridize with any of the other polynucleotides of the plurality of polynucleotides and wherein the polynucleotides of the plurality of polynucleotides are deoxyribonucleic or ribonucleic acid sequences, respectively having the same proportion of the four, natural or modified, bases A, C, G, and T, or A, C, G and U.

Abstract: The present invention generally relates to an apparatus for structural mapping of a macromolecule comprising an amount of persulfide effective to generate hydroxyl radicals upon contact with an aqueous solution. The present invention further relates to methods for structural mapping a macromolecule in an aqueous solution and methods for structural mapping a plurality of macromolecules in parallel, wherein each macromolecule is in a separate aqueous solution.

Abstract: Described are methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid, such as blood serum.

Abstract: The invention provides a method of determining a susceptibility of a subject for development of ADHD. The method comprises obtaining a sample from the subject, analyzing the sample for an ADHD susceptibility haplotype of LPHN3 receptor which is associated with at least one genetic marker selected from the group consisting of rs7678046, rs1901223, rs6813183, and rs1355368, and determining if the subject has a susceptibility to develop ADHD, whereby the presence of the haplotype having one or more of the genetic markers is indicative of a susceptibility to develop ADHD. The invention also provides methods of treating ADHD.

Abstract: A polymeric sensing fluid for detecting the presence of glucose and systems and methods of its use are generally disclosed. The polymeric sensing fluid includes a polymer in a solvent (e.g., an aqueous solvent). The polymer has a plurality of boronic acid moieties extending from its polymeric backbone. As such, the polymeric sensing fluid is configured to increase in viscosity upon addition of glucose due to crosslinking between the boronic acid moieties of the polymer and glucose.

Abstract: A system for detection of nucleic acids can include an excitation source configured to transmit excitation energy to a reaction site including a single molecule of nucleic acid reacted with a two-photon absorption moiety. The system also can include an optical system configured to focus the excitation energy transmitted from the excitation source to a focal region containing the reaction site, wherein said excitation energy within the focal region is sufficient to cause two-photon absorption by the two-photon absorption moiety. The system can further include a detector configured to detect emissions generated at the reaction site resulting from two-photon absorption of the excitation energy by the two-photon absorption moiety.

Abstract: Disclosed are methods for screening therapeutics, prophylactics or pain alleviators for diseases induced by TNF-?, a main mediator of inflammation and in ROS production and cell death, and for diagnosing the diseases, and a diagnostic kit. For this, a nucleotide sequence and an amino acid sequence of Romo1, which plays an important role in the ROS production and cell death pathway of TNF-? signaling are utilized.

Abstract: The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1)a and/or heterocycle 2 (Het-2)b and/or heterocycle 3 (Het-3)c and/or heterocycle 4 (Het-4)d of formulae I, II, III and IV respectively, the N-oxides, the pharmaceutically acceptable addition salts. The compounds claimed are suitable for the treatment of cancer.

Abstract: A microfluidic device for analyzing and/or sorting biological materials (e.g., molecules such as polynucleotides and polypeptides, including proteins and enzymes; viruses and cells) and methods for its use are provided. The device and methods of the invention are useful for sorting particles, e.g. virions. The invention is also useful for high throughput screening, e.g. combinatorial screening. The microfluidic device comprises a main channel and an inlet region in communication with the main channel at a droplet extrusion region. Droplets of solution containing the biological material are deposited into the main channel through the droplet extrusion region. A fluid different from and incompatible with the solution containing the biological material flows through the main channel so that the droplets containing the biological material do not diffuse or mix.

Abstract: The invention relates to a method for analysis of the AT/GC ratio of DNA by stretching the DNA in nanochannels and performing melting mapping of the AT/GC ratio along the DNA molecule.

Abstract: A system and method for preparing and testing of targeted nucleic acids is presented. The system integrates a pipetter, extractor, assay reader, and other components, including a selectively compliant articulated robot arm (SCARA). This synergistic integration of previously separate diagnostic tools creates a system and method whereby a minimum of human intervention is required. The resulting system provides a substantially more accurate and precise method of isolating, amplifying and detecting targeted nucleic acids for diagnosing diseases.

Abstract: The discovery that alterations in methylation, which can cause one or more genes on the single X chromosome in males to be partially silenced or overexpressed, constitute a predisposition to autism spectrum disorders is generally disclosed herein. These alterations provide the rationale and basis for methods to diagnose autism spectrum disorders.

Abstract: Methods for treating autoimmune disease using one or more inhibitor of STAT3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject. The present invention demonstrates that inhibition of STAT3 prevents development of autoimmune disease in vivo. Based on this finding, Stat3 inhibitors can be used to treat and/or diagnose autoimmune disease in a subject.

Abstract: The present invention relates to a polynucleotide encoding a protein comprising an amino acid sequence shown in SEQ ID NO: 2, wherein the protein encoded by the polynucleotide has a hyaluronic acid binding ability, the protein, a method for measuring hyaluronic acid using the protein, and a reagent kit for measuring hyaluronic acid comprising the protein as a constituent.

Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.

Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development.

Abstract: A labeling dye of the present invention includes a coloring portion comprising an organic EL-dye, a bonding portion to be bonded with a biomolecule and a spacer portion for linking the coloring portion and the bonding portion. The present invention provides a high incorporation ratio and also high fluorescence intensity in solid state.

Abstract: Methods for efficiently capturing a target nucleic acid from a sample by using a mixture that contains a capture probe specific for the target nucleic acid, the target nucleic acid, and a denaturant chemical, which mixture is incubated at elevated temperature for a short time, are disclosed. Compositions that include a capture probe that specifically binds to a target nucleic acid and a denaturant chemical, which when mixed with the target nucleic acid and incubated at elevated temperature for a short time, promote efficient hybridization of the capture probe and target nucleic acid are disclosed.

Abstract: The present invention relates to a marker that can be used as aging biomarker. More specifically, the present invention relates to the analysis of N-glycans in serum and its relation to the virtual age of the subject. This aging biomarker can be used to study the effect of medication, food compounds and/or special diets on the wellness and virtual age of animals, including humans.

Abstract: A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject.

Abstract: The invention relates to the use of at least two different fluorophores for configuring a fluorescence resonance energy transfer pair (FRET pair), wherein at least one first fluorophore (A) serves as the donor fluorophore and at least one second fluorophore (B) serves as the acceptor fluorophore within the FRET pair, wherein the first fluorophore (A) and the second fluorophore (B), independently of each other, each are configured on the basis of an organo-metal complex of rare earth elements, wherein the fluorophores (A) and (B) comprise different rare earth elements from each other.

Abstract: The invention provides Stat3 and Tyk2 targets that have importance for diagnosis of neurode-generative diseases such as Alzheimer's disease. Stat3 and Tyk2 are also important as targets for drug development for neurodegenerative diseases.

Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NF?B activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NF?B transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.